Related Experiment Videos

Progression after chronic manganese exposure

C C Huang1, C S Lu, N S Chu

  • 1Department of Neurology, Chang Gung Medical College and Memorial Hospital, Taipei, Taiwan.

Neurology
|August 1, 1993
PubMed

Insights

Chronic manganese exposure causes parkinsonism with progressive symptoms, even after exposure stops. Levodopa treatment offers limited, temporary relief in these patients.

Area of Science:

  • Neurology
  • Environmental Health
  • Toxicology

Background:

  • Manganese exposure can lead to parkinsonism, a neurological disorder.
  • Longitudinal studies are crucial for understanding disease progression after exposure cessation.

Purpose of the Study:

  • To assess the long-term progression of parkinsonian symptoms in patients after stopping manganese exposure.
  • To evaluate the efficacy and duration of levodopa treatment in manganese-induced parkinsonism.

Main Methods:

  • Longitudinal follow-up of six patients with chronic manganese-induced parkinsonism.
  • Clinical assessment of parkinsonian symptoms and disability scores (King's College Hospital Rating Scale).
  • Video recording analysis to confirm symptom progression, particularly gait disturbances.

Main Results:

  • Parkinsonian symptoms, especially gait issues like freezing and retropulsion, showed slow but significant progression over time.
  • Mean disability scores increased from 15.0 in 1987 to 28.3 in 1991 (p=0.003).
  • Levodopa provided initial improvement in three patients, but the response diminished within 2-3 years without causing dyskinesia or on-off fluctuations.

Conclusions:

  • Manganese-induced parkinsonism can lead to worsening neurological dysfunction years after manganese exposure ceases.
  • Patients with manganese-induced parkinsonism exhibit distinct responses to levodopa compared to those with idiopathic Parkinson's disease.

Related Concept Videos